Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BEAMNASDAQ:GMTXNASDAQ:STOKNASDAQ:TARS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBEAMBeam Therapeutics$17.05+1.3%$18.29$13.52▼$35.25$1.72B2.351.96 million shs702,215 shsGMTXGemini Therapeutics$47.37-1.4%$45.76$1.16▼$14.10$2.05B-0.12189,291 shs132,011 shsSTOKStoke Therapeutics$9.16-2.1%$8.28$5.35▼$17.58$501.47M1.2710,367 shs254,794 shsTARSTarsus Pharmaceuticals$42.11-2.0%$47.60$20.08▼$57.28$1.76B0.94679,907 shs321,447 shsInvesting Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBEAMBeam Therapeutics0.00%-4.70%-13.78%-43.60%-30.80%GMTXGemini Therapeutics0.00%-1.50%+4.29%-13.31%+38.19%STOKStoke Therapeutics0.00%-4.78%-4.10%+13.45%-35.05%TARSTarsus Pharmaceuticals0.00%-4.51%-14.04%+4.09%+22.76%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBEAMBeam Therapeutics3.2396 of 5 stars4.51.00.00.03.62.50.6GMTXGemini TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ASTOKStoke Therapeutics3.528 of 5 stars3.60.00.04.83.01.70.0TARSTarsus Pharmaceuticals3.0797 of 5 stars4.51.00.00.02.92.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBEAMBeam Therapeutics 3.00Buy$48.75185.91% UpsideGMTXGemini Therapeutics 0.00N/AN/AN/ASTOKStoke Therapeutics 3.29Buy$23.20153.28% UpsideTARSTarsus Pharmaceuticals 3.00Buy$66.1757.15% UpsideCurrent Analyst Ratings BreakdownLatest STOK, TARS, GMTX, and BEAM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/27/2025TARSTarsus PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$72.005/14/2025STOKStoke TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/14/2025STOKStoke TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$47.00 ➝ $35.005/7/2025BEAMBeam TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$78.00 ➝ $55.005/7/2025BEAMBeam TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$75.00 ➝ $70.005/7/2025BEAMBeam TherapeuticsBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$31.00 ➝ $25.005/5/2025TARSTarsus PharmaceuticalsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$46.00 ➝ $51.005/2/2025TARSTarsus PharmaceuticalsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$78.00 ➝ $84.004/9/2025STOKStoke TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$22.00 ➝ $22.004/7/2025BEAMBeam TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$80.00 ➝ $80.003/28/2025BEAMBeam TherapeuticsBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$42.00 ➝ $42.00(Data available from 5/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBEAMBeam Therapeutics$63.58M26.97N/AN/A$12.04 per share1.42GMTXGemini TherapeuticsN/AN/AN/AN/A$2.89 per shareN/ASTOKStoke Therapeutics$190.91M2.62N/AN/A$3.57 per share2.57TARSTarsus Pharmaceuticals$233.67M7.57N/AN/A$5.95 per share7.08Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBEAMBeam Therapeutics-$132.53M-$4.61N/AN/AN/A-41.07%-16.22%-10.94%8/5/2025 (Estimated)GMTXGemini Therapeutics-$71.87M-$1.00N/AN/AN/AN/A-38.78%-35.88%N/ASTOKStoke Therapeutics-$104.70M$0.79N/AN/AN/A-629.90%-54.45%-40.77%8/5/2025 (Estimated)TARSTarsus Pharmaceuticals-$135.89M-$2.73N/AN/AN/A-103.64%-55.86%-39.28%8/6/2025 (Estimated)Latest STOK, TARS, GMTX, and BEAM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/6/2025Q1 2025BEAMBeam Therapeutics-$1.11-$1.24-$0.13-$1.24$14.69 million$7.47 million5/1/2025Q1 2025TARSTarsus Pharmaceuticals-$0.69-$0.64+$0.05-$0.64$72.50 million$78.34 million3/24/2025Q4 2024STOKStoke Therapeutics-$0.56-$0.18+$0.38-$0.18$4.20 million$22.61 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBEAMBeam Therapeutics$0.905.28%N/AN/A N/AGMTXGemini TherapeuticsN/AN/AN/AN/AN/ASTOKStoke TherapeuticsN/AN/AN/AN/AN/ATARSTarsus PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBEAMBeam TherapeuticsN/A5.695.69GMTXGemini TherapeuticsN/A71.4971.49STOKStoke TherapeuticsN/A5.095.09TARSTarsus Pharmaceuticals0.305.425.38Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBEAMBeam Therapeutics99.68%GMTXGemini Therapeutics75.42%STOKStoke TherapeuticsN/ATARSTarsus Pharmaceuticals90.01%Insider OwnershipCompanyInsider OwnershipBEAMBeam Therapeutics4.20%GMTXGemini Therapeutics12.90%STOKStoke Therapeutics11.30%TARSTarsus Pharmaceuticals8.25%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBEAMBeam Therapeutics510100.56 million79.33 millionOptionableGMTXGemini Therapeutics3043.33 million37.74 millionNot OptionableSTOKStoke Therapeutics10054.60 million46.98 millionOptionableTARSTarsus Pharmaceuticals5042.01 million35.07 millionOptionableSTOK, TARS, GMTX, and BEAM HeadlinesRecent News About These CompaniesTFG Asset Management GP Ltd Sells 414,117 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)May 27 at 6:03 AM | marketbeat.comToronto Dominion Bank Acquires New Position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)May 27 at 5:15 AM | marketbeat.comWoodline Partners LP Buys 37,417 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)May 26 at 4:36 AM | marketbeat.comTarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Receives Average Recommendation of "Buy" from BrokeragesMay 25 at 1:31 AM | marketbeat.comTarsus Pharmaceuticals (NASDAQ:TARS) Cut to Hold at Wall Street ZenMay 24 at 11:53 AM | marketbeat.comTarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Shares Purchased by Bank of America Corp DEMay 23, 2025 | marketbeat.comTarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Receives Average Rating of "Buy" from BrokeragesMay 23, 2025 | americanbankingnews.com59,204 Shares in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Purchased by Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A.May 22, 2025 | marketbeat.comOMERS ADMINISTRATION Corp Buys Shares of 7,400 Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)May 22, 2025 | marketbeat.comTarsus Pharmaceuticals at H.C. Wainwright: Expanding Horizons with XdemvyMay 21, 2025 | investing.comMillennium Management LLC Increases Stock Position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)May 20, 2025 | marketbeat.comDeutsche Bank AG Raises Position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)May 19, 2025 | marketbeat.comRTW Investments LP Has $179.21 Million Stake in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)May 18, 2025 | marketbeat.comNumerai GP LLC Purchases Shares of 18,668 Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)May 17, 2025 | marketbeat.comParadigm Biocapital Advisors LP Has $140.19 Million Stock Position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)May 16, 2025 | marketbeat.comTarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Shares Acquired by Northern Trust CorpMay 16, 2025 | marketbeat.comTarsus Pharmaceuticals (TARS) Loses -15.59% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerMay 14, 2025 | zacks.comIntegral Health Asset Management LLC Has $19.38 Million Holdings in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)May 14, 2025 | marketbeat.comD. E. Shaw & Co. Inc. Grows Stock Position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)May 14, 2025 | marketbeat.comEnsign Peak Advisors Inc Decreases Holdings in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)May 13, 2025 | marketbeat.comTarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Shares Sold by Schonfeld Strategic Advisors LLCMay 13, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSTOK, TARS, GMTX, and BEAM Company DescriptionsBeam Therapeutics NASDAQ:BEAM$17.05 +0.22 (+1.31%) As of 02:27 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.Gemini Therapeutics NASDAQ:GMTX$47.37 -0.67 (-1.39%) As of 05/23/2025Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 for treatment of systemic diseases. Gemini Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.Stoke Therapeutics NASDAQ:STOK$9.16 -0.20 (-2.14%) As of 02:26 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels. Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. The company also develops STK-001, which is in phase I/II clinical trial to treat Dravet syndrome; and programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye. The company has a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.Tarsus Pharmaceuticals NASDAQ:TARS$42.10 -0.88 (-2.04%) As of 02:27 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other infectious disease prevention. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir Scores First $1 Billion Contract; Is It Priced In? Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 Earnings Navitas Soars on NVIDIA Deal: Breaking Down its Tech and Outlook MarketBeat Week in Review – 05/19 - 05/23 Workday Stock Price Implosion: An Automatic Buy for AI Investors Can Ross Stores Be the Safety Cushion In Retail Stocks? MercadoLibre Is Soaring—Should You Wait for a Better Entry? Trade Desk Silences Critics; Recovery Looks Poised to Continue Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
